IIQ
vs
S
S&P/ASX 300
IIQ
Over the past 12 months, IIQ has underperformed S&P/ASX 300, delivering a return of -56% compared to S&P/ASX 300's +2% growth.
Stocks Performance
IIQ vs S&P/ASX 300
Performance Gap
IIQ vs S&P/ASX 300
Performance By Year
IIQ vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
INOVIQ Ltd
Glance View
INOVIQ Ltd is an Australian life sciences company focused on cancer diagnostics and exosome-based tools. Its main work is to develop blood tests and related technologies that help detect cancer earlier, with a particular emphasis on ovarian and breast cancer. The company also works on exosome science, which uses tiny particles released by cells as a source of diagnostic and research information. The company sells and develops diagnostic products and intellectual property, rather than drugs or hospital services. Its customers and partners are typically hospitals, pathology groups, research organizations, and other biotech or diagnostics companies that need cancer-testing technology or access to its patents and know-how. INOVIQ makes money through product sales, licensing, research collaborations, and commercialization agreements tied to its tests and technology. What makes INOVIQ different is its role in the medical testing value chain: it sits between basic research and routine clinical use. Instead of treating cancer, it aims to improve how cancer is detected and understood, which can make it a useful partner for labs and healthcare companies looking for non-invasive testing methods.
